ProNephro (NGAL) now available through Roche Diagnostics.

Financials

Summary of Key Figures

More detailed information and explanations can be found in our Interim reports and Annual Report.

(1,000 DKK)20242023202220212020
Revenue36,24330,95828,96924,25423,204
Operating profit/loss before interest and tax (EBIT)(75,452)(61,172)81,527(65,255)(63,590)
Operating profit/loss before tax(73,743)(61,207)(81,547)(63,840)(66,834)
Net Loss(68,243)(56,328)(75,923)(57,113)(61,562)